Introduction <p>Breast cancer remains the most frequently diagnosed malignancy among women worldwide. Advances in treatment with the approval of multiple novel therapeutics have led to significant improvements in long-term survival and reduced mortality. Although clinicians are familiar with the more common toxicities linked to targeted therapies, ocular adverse effects often receive less attention. Increasing provider awareness of these potential eye-related toxicities is essential to ensure prompt recognition and timely referral to ophthalmologists for early intervention.</p> Methods <p>We reviewed evidence on the prevalence, characteristics, and management of ocular toxicities associated with novel targeted breast cancer therapies.</p> Conclusion <p>This review summarizes the major ocular toxicities linked to targeted therapies used in breast cancer and describes current strategies for their effective clinical management.</p>